You just read:

Rigel Announces FDA Approval of TAVALISSE™ (fostamatinib disodium hexahydrate) for Chronic Immune Thrombocytopenia (ITP) in Adult Patients

News provided by

Rigel Pharmaceuticals, Inc.

Apr 17, 2018, 04:51 ET